공시 • Mar 20
PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026 PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate. 공시 • Jun 22
PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021 PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation. 공시 • Jun 18
PAOG Plans to Launch CBD Nutraceuticals Line of Products PAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT. 공시 • May 08
Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of Products PAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor. 공시 • Oct 16
PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two Weeks PAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative. 공시 • Jul 18
PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY). PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.